Paul Stewart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul Stewart has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Donna M. Evon
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, USA
3 shared publications - Alfred Sidney Barritt
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA
2 shared publications - Kim L. R. Brouwer
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
2 shared publications Nancy Reau
Department of Internal Medicine, Section of Hepatology, Rush University, Chicago, Illinois, United States of America
2 shared publications- Wei Jia
Center for Translational Medicine, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, China
2 shared publications Ada Cachafeiro
The University of North Carolina at Chapel Hill, Department of Biostatistics, Chapel Hill, NC, United States
1 shared publication
Latest Publications
- Open Access
- 20 November 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (12)
Group-based telehealth stress management—lifestyle interventions are feasible for patients with chronic liver disease
Background: Group-based, telehealth behavioral interventions may be efficient, effective, and acceptable treatment modalities for patients with chronic liver diseases; however, pilot feasibility and patient satisfaction data are needed to justify efficacy trials. Given the poor quality of life, symptoms, and health risk factors, patients with chronic hepatitis C–associated liver disease (HCV-LD) may benefit from psychosocial interventions. A pilot feasibility study of a videoconferencing-delivered cognitive behavioral coping skills intervention (“VC-CBCS”) was conducted to evaluate multiple indicators of feasibility, levels of patient satisfaction, and changes in patient-reported outcomes (PROs). Methods: We pilot tested a 14-week, 90-minute VC-CBCS intervention by conducting a small randomized controlled trial. Thirty-two adults with HCV-LD and high stress/symptom levels were randomized to the protocolized VC-CBCS intervention (n=24) or standard of care (n=8), in 4 waves of 7–9 participants in 2020–2021. Results: Based upon rates of approach to enrollment (60%), retention (84%), PRO data collection (99.4%), and session attendance (91%), a future efficacy trial appears highly feasible. Levels of participant satisfaction were encouraging for VC delivery, intervention content and structure, and group processes. Technological and behavioral issues were minor. Collection of in-home saliva testing was not feasible. Moderate to large pre–post-intervention effect sizes were observed for some mediators (perceived stress, coping, relaxation, self-efficacy, sleep hygiene), with some of these changes correlating with small to moderate improvements in mental health and symptoms (eg, depression, fatigue; effect size range: 0.23–0.47). No consistent patterns were evident between changes in eating and exercise behaviors and PROs. Conclusions: A group-based VC-CBCS intervention appears feasible and may address unmet psychosocial needs in patients living with chronic liver disease.
- 20 November 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (12)
Open AccessGroup-based telehealth stress management—lifestyle interventions are feasible for patients with chronic liver disease
Background: Group-based, telehealth behavioral interventions may be efficient, effective, and acceptable treatment modalities for patients with chronic liver diseases; however, pilot feasibility and patient satisfaction data are needed to justify efficacy trials. Given the poor quality of life, symptoms, and health risk factors, patients with chronic hepatitis C–associated liver disease (HCV-LD) may benefit from psychosocial interventions. A pilot feasibility study of a videoconferencing-delivered cognitive behavioral coping skills intervention (“VC-CBCS”) was conducted to evaluate multiple indicators of feasibility, levels of patient satisfaction, and changes in patient-reported outcomes (PROs). Methods: We pilot tested a 14-week, 90-minute VC-CBCS intervention by conducting a small randomized controlled trial. Thirty-two adults with HCV-LD and high stress/symptom levels were randomized to the protocolized VC-CBCS intervention (n=24) or standard of care (n=8), in 4 waves of 7–9 participants in 2020–2021. Results: Based upon rates of approach to enrollment (60%), retention (84%), PRO data collection (99.4%), and session attendance (91%), a future efficacy trial appears highly feasible. Levels of participant satisfaction were encouraging for VC delivery, intervention content and structure, and group processes. Technological and behavioral issues were minor. Collection of in-home saliva testing was not feasible. Moderate to large pre–post-intervention effect sizes were observed for some mediators (perceived stress, coping, relaxation, self-efficacy, sleep hygiene), with some of these changes correlating with small to moderate improvements in mental health and symptoms (eg, depression, fatigue; effect size range: 0.23–0.47). No consistent patterns were evident between changes in eating and exercise behaviors and PROs. Conclusions: A group-based VC-CBCS intervention appears feasible and may address unmet psychosocial needs in patients living with chronic liver disease.
- 24 September 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (2) , 353-364
Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease
Aims: Serum, liver and urinary bile acids are increased, and hepatic transport protein levels are decreased in a non‐clinical model of polycystic kidney disease. Similar changes in patients with autosomal dominant polycystic kidney disease (ADPKD) may predispose them to drug‐induced liver injury (DILI) and hepatic drug–drug interactions (DDIs). Systemic coproporphyrin‐I (CP‐I), an endogenous biomarker for hepatic OATP1B function and MRP2 substrate, is used to evaluate OATP1B‐mediated DDI risk in humans. In this clinical observational cohort‐comparison study, bile acid profiles and CP‐I concentrations in healthy volunteers and patients with ADPKD were compared.Methods: Serum and urine samples from healthy volunteers (n = 16) and patients with ADPKD (n = 8) were collected. Serum bile acids, and serum and urine CP‐I concentrations, were quantified by ultra‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS).Results: Patients with ADPKD exhibited increased serum concentrations of total (1.3‐fold) and taurine‐conjugated (2.8‐fold) bile acids compared to healthy volunteers. Specifically, serum concentrations of six bile acids known to be more hydrophobic/hepatotoxic (glycochenodeoxycholate, taurochenodeoxycholate, taurodeoxycholate, lithocholate, glycolithocholate and taurolithocholate) were increased (1.5‐, 2.9‐, 2.8‐, 1.6‐, 1.7‐ and 2.7‐fold, respectively) in patients with ADPKD. Furthermore, serum CP‐I concentrations were elevated and the renal clearance of CP‐I was reduced in patients with ADPKD compared to healthy volunteers.Conclusions: Increased exposure to bile acids may increase susceptibility to DILI in some patients with ADPKD. Furthermore, the observed increase in serum CP‐I concentrations could be attributed, in part, to impaired OATP1B function in patients with ADPKD, which could increase the risk of DDIs involving OATP1B substrates compared to healthy volunteers.
- 24 September 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (2) , 353-364
Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease
Aims: Serum, liver and urinary bile acids are increased, and hepatic transport protein levels are decreased in a non‐clinical model of polycystic kidney disease. Similar changes in patients with autosomal dominant polycystic kidney disease (ADPKD) may predispose them to drug‐induced liver injury (DILI) and hepatic drug–drug interactions (DDIs). Systemic coproporphyrin‐I (CP‐I), an endogenous biomarker for hepatic OATP1B function and MRP2 substrate, is used to evaluate OATP1B‐mediated DDI risk in humans. In this clinical observational cohort‐comparison study, bile acid profiles and CP‐I concentrations in healthy volunteers and patients with ADPKD were compared.Methods: Serum and urine samples from healthy volunteers (n = 16) and patients with ADPKD (n = 8) were collected. Serum bile acids, and serum and urine CP‐I concentrations, were quantified by ultra‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS).Results: Patients with ADPKD exhibited increased serum concentrations of total (1.3‐fold) and taurine‐conjugated (2.8‐fold) bile acids compared to healthy volunteers. Specifically, serum concentrations of six bile acids known to be more hydrophobic/hepatotoxic (glycochenodeoxycholate, taurochenodeoxycholate, taurodeoxycholate, lithocholate, glycolithocholate and taurolithocholate) were increased (1.5‐, 2.9‐, 2.8‐, 1.6‐, 1.7‐ and 2.7‐fold, respectively) in patients with ADPKD. Furthermore, serum CP‐I concentrations were elevated and the renal clearance of CP‐I was reduced in patients with ADPKD compared to healthy volunteers.Conclusions: Increased exposure to bile acids may increase susceptibility to DILI in some patients with ADPKD. Furthermore, the observed increase in serum CP‐I concentrations could be attributed, in part, to impaired OATP1B function in patients with ADPKD, which could increase the risk of DDIs involving OATP1B substrates compared to healthy volunteers.
- Open Access
Low Energy Availability (LEA) and Hypertension in Black Division I Collegiate Athletes: A Novel Pilot Study
The purpose of this study was to investigate the relationship between low energy availability (LEA) and nutritional content with high blood pressure (HBP) in African American Division I athletes. Twenty-three D1 African American pre-season athletes were recruited to participate. HBP was defined as >120 systolic blood pressure (BP) and R = 0.56) with 14/23 having HBP. Of the 14 athletes observed with HBP, 78.5% (11/14) were calorically deficient (−529 ± 695 kcal) with an OR of 7.2. Micronutrient intake deficiencies were ubiquitous among the 23 HBP athletes: poly-unsaturated fatty acid −29.6%; omega-3 −26.0%; iron −46.0%; calcium −25.1%; and sodium −14.2%, amongst others. LEA and micronutrient deficiencies may contribute to HBP in Black D1 athletes, which has been shown to be the most common modifiable risk factor to decrease the risk of sudden cardiac death.
Open AccessLow Energy Availability (LEA) and Hypertension in Black Division I Collegiate Athletes: A Novel Pilot Study
The purpose of this study was to investigate the relationship between low energy availability (LEA) and nutritional content with high blood pressure (HBP) in African American Division I athletes. Twenty-three D1 African American pre-season athletes were recruited to participate. HBP was defined as >120 systolic blood pressure (BP) and R = 0.56) with 14/23 having HBP. Of the 14 athletes observed with HBP, 78.5% (11/14) were calorically deficient (−529 ± 695 kcal) with an OR of 7.2. Micronutrient intake deficiencies were ubiquitous among the 23 HBP athletes: poly-unsaturated fatty acid −29.6%; omega-3 −26.0%; iron −46.0%; calcium −25.1%; and sodium −14.2%, amongst others. LEA and micronutrient deficiencies may contribute to HBP in Black D1 athletes, which has been shown to be the most common modifiable risk factor to decrease the risk of sudden cardiac death.
- Open Access
- 1 August 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (8) , e0196908
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study
Symptom burden, medical comorbidities, and functional well-being of patients with chronic hepatitis C virus (HCV) initiating direct acting antiviral (DAA) therapy in real-world clinical settings are not known. We characterized these patient-reported outcomes (PROs) among HCV-infected patients and explored associations with sociodemographic, liver disease, and psychiatric/substance abuse variables. PROP UP is a large US multicenter observational study that enrolled 1,600 patients with chronic HCV in 2016–2017. Data collected prior to initiating DAA therapy assessed the following PROs: number of medical comorbidities; neuropsychiatric, somatic, gastrointestinal symptoms (PROMIS surveys); overall symptom burden (Memorial Symptom Assessment Scale); and functional well-being (HCV-PRO). Candidate predictors included liver disease markers and patient-reported sociodemographic, psychiatric, and alcohol/drug use features. Predictive models were explored using a random selection of 700 participants; models were then validated with data from the remaining 900 participants. The cohort was 55% male, 39% non-white, 48% had cirrhosis (12% with advanced cirrhosis); 52% were disabled or unemployed; 63% were on public health insurance or uninsured; and over 40% had markers of psychiatric illness. The median number of medical comorbidities was 4 (range: 0–15), with sleep disorders, chronic pain, diabetes, joint pain and muscle aches being present in 20–50%. Fatigue, sleep disturbance, pain and neuropsychiatric symptoms were present in over 60% and gastrointestinal symptoms in 40–50%. In multivariable validation models, the strongest and most frequent predictors of worse PROs were disability, unemployment, and use of psychiatric medications, while liver markers generally were not. This large multi-center cohort study provides a comprehensive and contemporary assessment of the symptom burden and comorbid medical conditions in patients with HCV treated in real world settings. Pain, fatigue, and sleep disturbance were common and often severe. Sociodemographic and psychiatric markers were the most robust predictors of PROs. Future research that includes a rapidly changing population of HCV-infected individuals needs to evaluate how DAA therapy affects PROs and elucidate which symptoms resolve with viral eradication. (Clinicaltrial.gov: NCT02601820).
- 1 August 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (8) , e0196908
Open AccessA comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study
Symptom burden, medical comorbidities, and functional well-being of patients with chronic hepatitis C virus (HCV) initiating direct acting antiviral (DAA) therapy in real-world clinical settings are not known. We characterized these patient-reported outcomes (PROs) among HCV-infected patients and explored associations with sociodemographic, liver disease, and psychiatric/substance abuse variables. PROP UP is a large US multicenter observational study that enrolled 1,600 patients with chronic HCV in 2016–2017. Data collected prior to initiating DAA therapy assessed the following PROs: number of medical comorbidities; neuropsychiatric, somatic, gastrointestinal symptoms (PROMIS surveys); overall symptom burden (Memorial Symptom Assessment Scale); and functional well-being (HCV-PRO). Candidate predictors included liver disease markers and patient-reported sociodemographic, psychiatric, and alcohol/drug use features. Predictive models were explored using a random selection of 700 participants; models were then validated with data from the remaining 900 participants. The cohort was 55% male, 39% non-white, 48% had cirrhosis (12% with advanced cirrhosis); 52% were disabled or unemployed; 63% were on public health insurance or uninsured; and over 40% had markers of psychiatric illness. The median number of medical comorbidities was 4 (range: 0–15), with sleep disorders, chronic pain, diabetes, joint pain and muscle aches being present in 20–50%. Fatigue, sleep disturbance, pain and neuropsychiatric symptoms were present in over 60% and gastrointestinal symptoms in 40–50%. In multivariable validation models, the strongest and most frequent predictors of worse PROs were disability, unemployment, and use of psychiatric medications, while liver markers generally were not. This large multi-center cohort study provides a comprehensive and contemporary assessment of the symptom burden and comorbid medical conditions in patients with HCV treated in real world settings. Pain, fatigue, and sleep disturbance were common and often severe. Sociodemographic and psychiatric markers were the most robust predictors of PROs. Future research that includes a rapidly changing population of HCV-infected individuals needs to evaluate how DAA therapy affects PROs and elucidate which symptoms resolve with viral eradication. (Clinicaltrial.gov: NCT02601820).
- 1 April 2017
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 36 (4) , S311-S312
Cytokine Levels in Steen Solution Perfusate Increase During Ex-Vivo Lung Perfusion (EVLP) of Lungs from Conventional Donors (Conv) and Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs)
- 1 April 2017
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 36 (4) , S311-S312
Cytokine Levels in Steen Solution Perfusate Increase During Ex-Vivo Lung Perfusion (EVLP) of Lungs from Conventional Donors (Conv) and Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs)
- Top Cited Papers
- 3 July 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (11) , 3318-3328
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
Background and Aims The prevalence of nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) is increasing at an alarming rate. The role of bile acids in the development and progression of NAFLD to NASH and cirrhosis is poorly understood. This study aimed to quantify the bile acid metabolome in healthy subjects and patients with non-cirrhotic NASH under fasting conditions and after a standardized meal. Methods Liquid chromatography tandem mass spectroscopy was used to quantify 30 serum and 16 urinary bile acids from 15 healthy volunteers and 7 patients with biopsy-confirmed NASH. Bile acid concentrations were measured at two fasting and four post-prandial time points following a high-fat meal to induce gallbladder contraction and bile acid reabsorption from the intestine. Results Patients with NASH had significantly higher total serum bile acid concentrations than healthy subjects under fasting conditions (2.2- to 2.4-fold increase in NASH; NASH 2595–3549 µM and healthy 1171–1458 µM) and at all post-prandial time points (1.7- to 2.2-fold increase in NASH; NASH 4444–5898 µM and healthy 2634–2829 µM). These changes were driven by increased taurine- and glycine-conjugated primary and secondary bile acids. Patients with NASH exhibited greater variability in their fasting and post-prandial bile acid profile. Conclusions Results indicate that patients with NASH have higher fasting and post-prandial exposure to bile acids, including the more hydrophobic and cytotoxic secondary species. Increased bile acid exposure may be involved in liver injury and the pathogenesis of NAFLD and NASH.
- 3 July 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (11) , 3318-3328
Top Cited PapersAltered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
Background and Aims The prevalence of nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) is increasing at an alarming rate. The role of bile acids in the development and progression of NAFLD to NASH and cirrhosis is poorly understood. This study aimed to quantify the bile acid metabolome in healthy subjects and patients with non-cirrhotic NASH under fasting conditions and after a standardized meal. Methods Liquid chromatography tandem mass spectroscopy was used to quantify 30 serum and 16 urinary bile acids from 15 healthy volunteers and 7 patients with biopsy-confirmed NASH. Bile acid concentrations were measured at two fasting and four post-prandial time points following a high-fat meal to induce gallbladder contraction and bile acid reabsorption from the intestine. Results Patients with NASH had significantly higher total serum bile acid concentrations than healthy subjects under fasting conditions (2.2- to 2.4-fold increase in NASH; NASH 2595–3549 µM and healthy 1171–1458 µM) and at all post-prandial time points (1.7- to 2.2-fold increase in NASH; NASH 4444–5898 µM and healthy 2634–2829 µM). These changes were driven by increased taurine- and glycine-conjugated primary and secondary bile acids. Patients with NASH exhibited greater variability in their fasting and post-prandial bile acid profile. Conclusions Results indicate that patients with NASH have higher fasting and post-prandial exposure to bile acids, including the more hydrophobic and cytotoxic secondary species. Increased bile acid exposure may be involved in liver injury and the pathogenesis of NAFLD and NASH.
- Open Access
- 15 April 2013
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 13 (1) , 1-13
Confidence regions for repeated measures ANOVA power curves based on estimated covariance
Using covariance or mean estimates from previous data introduces randomness into each power value in a power curve. Creating confidence intervals about the power estimates improves study planning by allowing scientists to account for the uncertainty in the power estimates. Driving examples arise in many imaging applications. We use both analytical and Monte Carlo simulation methods. Our analytical derivations apply to power for tests with the univariate approach to repeated measures (UNIREP). Approximate confidence intervals and regions for power based on an estimated covariance matrix and fixed means are described. Extensive simulations are used to examine the properties of the approximations. Closed-form expressions are given for approximate power and confidence intervals and regions. Monte Carlo simulations support the accuracy of the approximations for practical ranges of sample size, rank of the design matrix, error degrees of freedom, and the amount of deviation from sphericity. The new methods provide accurate coverage probabilities for all four UNIREP tests, even for small sample sizes. Accuracy is higher for higher power values than for lower power values, making the methods especially useful in practical research conditions. The new techniques allow the plotting of power confidence regions around an estimated power curve, an approach that has been well received by researchers. Free software makes the new methods readily available. The new techniques allow a convenient way to account for the uncertainty of using an estimated covariance matrix in choosing a sample size for a repeated measures ANOVA design. Medical imaging and many other types of healthcare research often use repeated measures ANOVA.
- 15 April 2013
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 13 (1) , 1-13
Open AccessConfidence regions for repeated measures ANOVA power curves based on estimated covariance
Using covariance or mean estimates from previous data introduces randomness into each power value in a power curve. Creating confidence intervals about the power estimates improves study planning by allowing scientists to account for the uncertainty in the power estimates. Driving examples arise in many imaging applications. We use both analytical and Monte Carlo simulation methods. Our analytical derivations apply to power for tests with the univariate approach to repeated measures (UNIREP). Approximate confidence intervals and regions for power based on an estimated covariance matrix and fixed means are described. Extensive simulations are used to examine the properties of the approximations. Closed-form expressions are given for approximate power and confidence intervals and regions. Monte Carlo simulations support the accuracy of the approximations for practical ranges of sample size, rank of the design matrix, error degrees of freedom, and the amount of deviation from sphericity. The new methods provide accurate coverage probabilities for all four UNIREP tests, even for small sample sizes. Accuracy is higher for higher power values than for lower power values, making the methods especially useful in practical research conditions. The new techniques allow the plotting of power confidence regions around an estimated power curve, an approach that has been well received by researchers. Free software makes the new methods readily available. The new techniques allow a convenient way to account for the uncertainty of using an estimated covariance matrix in choosing a sample size for a repeated measures ANOVA design. Medical imaging and many other types of healthcare research often use repeated measures ANOVA.
- 30 November 2010
- Published by Elsevier in Journal of Clinical Virology
- Vol. 49 (3) , 198-204
Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay
- 30 November 2010
- Published by Elsevier in Journal of Clinical Virology
- Vol. 49 (3) , 198-204
Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay
- Open Access
- 12 November 2009
- Published by Springer Nature in BMC Dermatology
- Vol. 9 (1) , 11
Attitudes of dermatologists in the southeastern United States regarding treatment of alopecia areata: a cross-sectional survey study
Background: Little evidence exists to guide treatment of alopecia areata (AA). The current practices in treatment of children compared to adults and of progressive stages of hair loss are unknown. The objective of this study was to examine the current practices of southeastern United States dermatologists for the treatment of AA. Methods: Dermatologists were sent anonymous questionnaires regarding their treatment practices by mail. Respondents' frequencies of treatment in children compared to adults and in patchy hair loss compared to widespread hair loss were compared with Wilcoxon signed-ranks tests and Friedman tests. As a secondary source, the National Alopecia Areata Registry (NAAR) database was analyzed for patients' treatment histories. Results: Survey results suggested that dermatologists recommend treatment less frequently for children than adults and for more advanced hair loss. NAAR data confirmed that offering no treatment for AA is relatively common. Conclusion: Dermatologists' treatment of AA is inconsistent. A stronger evidence base will provide more consistent treatment options.
- 12 November 2009
- Published by Springer Nature in BMC Dermatology
- Vol. 9 (1) , 11
Open AccessAttitudes of dermatologists in the southeastern United States regarding treatment of alopecia areata: a cross-sectional survey study
Background: Little evidence exists to guide treatment of alopecia areata (AA). The current practices in treatment of children compared to adults and of progressive stages of hair loss are unknown. The objective of this study was to examine the current practices of southeastern United States dermatologists for the treatment of AA. Methods: Dermatologists were sent anonymous questionnaires regarding their treatment practices by mail. Respondents' frequencies of treatment in children compared to adults and in patchy hair loss compared to widespread hair loss were compared with Wilcoxon signed-ranks tests and Friedman tests. As a secondary source, the National Alopecia Areata Registry (NAAR) database was analyzed for patients' treatment histories. Results: Survey results suggested that dermatologists recommend treatment less frequently for children than adults and for more advanced hair loss. NAAR data confirmed that offering no treatment for AA is relatively common. Conclusion: Dermatologists' treatment of AA is inconsistent. A stronger evidence base will provide more consistent treatment options.